UBS earlier maintained a Buy rating on Momenta Pharmaceuticals (NASDAQ: MNTA) and lowered its price target to $15.00 (from $18.00) ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE